Article Text

Download PDFPDF
A trial of oral delta-1-(trans)-tetrahydrocannabinol in reversible airways obstruction.
  1. B H Davies,
  2. S Radcliffe,
  3. A Seaton,
  4. J D Graham


    Sixteen patients with proven reversible airways obstruction were admitted to a double-blind study to compare the bronchodilator effects of oral delta-1-(trans)-tetrahydrocannabinol (delta-1-THC) and salbutamol. Measurements of forced vital capacity, forced expired volume in one second, peak expiratory flow rate, and maximum expiratory flow rate at 50 percent vital capacity after 10 mg oral delta-1-THC did not differ significantly from the effect of placebo, whereas increases after salbutamol were significant. Analyses of mood, pulse rate, blood pressure, and electrocardiogram showed no important changes after oral delta-1-THC. In vitro studies with isolated tracheal muscle indicate that the activity of delta-1-THC is 1,000 times less than the equivalent dose of isoprenaline, and the effect of delta-1-THC is not abolished by beta-adrenoreceptor blocking agents. It is concluded that oral delta-1-THC, at a dose of 10 mg, does not produce clinically significant bronchodilatation in patients with reversible airways obstruction.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.